Overview

Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer

Status:
Active, not recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
To evaluated the efficacy and safety of caldonirimab plus nimotuzumab as second-line or later therapy for recurrent or metastatic cervical cancer
Phase:
Phase 2
Details
Lead Sponsor:
Health Science Center of Xi'an Jiaotong University
Treatments:
Nimotuzumab